Premium
Charge‐conversional poly(amino acid)s derivatives as a drug delivery carrier in response to the tumor environment
Author(s) -
Yoon Se Rim,
Yang HeeMan,
Park Chan Woo,
Lim Sujin,
Chung Bong Hyun,
Kim JongDuk
Publication year - 2012
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.34048
Subject(s) - nanocarriers , materials science , micelle , drug delivery , doxorubicin , mtt assay , confocal microscopy , drug carrier , flow cytometry , biophysics , combinatorial chemistry , nanotechnology , organic chemistry , chemistry , biochemistry , cell , medicine , microbiology and biotechnology , biology , aqueous solution , surgery , chemotherapy
A charge‐converting and pH‐dependent nanocarrier was achieved by conjugating 2,3‐dimethylmaleic anhydride (DMMA) to the amino group of an octadecyl grafted poly (2‐hydroxyethyl aspartamide) (PHEA‐ g ‐C 18 ‐NH 2 ) backbone, thereby forming a spherical micelle. PHEA, a poly(amino acid)s derivative, was derived from poly(succinimide), which is biocompatible and biodegradable. DMMA, a detachable component at the tumor site, was added, preventing aggregation with negative blood serum and enhancing the nanocarrier's cellular uptake. The polymeric micelle was comprehensively characterized and doxorubicin was encapsulated successively. The cellular uptake and anticancer therapeutic effect were evaluated by flow cytometry, confocal laser scanning microscopy, and a MTT assay. The properties of the nanocarrier can further be exploited to develop an early detection module for cancer. The present work is also expected to advance the study of designing smart carriers for drug and gene delivery. © 2012 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2012.